Lp(a) Testing in Primary Prevention: Cost-Effective Strategy to Reduce Cardiovascular Risk
Atherosclerosis has shared a post on LinkedIn:
“Lp(a) Testing: A Cost-Saving Tool for Cardiovascular Prevention
High Lp(a) levels are a known cardiovascular risk factor, but is testing for Lp(a) worth it from a healthcare perspective?
A recent microsimulation study modeled 10,000 adults aged 40–69 without prior CVD from the UK Biobank. The study evaluated Lp(a) testing in individuals not initially high-risk. Those with Lp(a) ≥105 nmol/L were reclassified as high-risk and received statins and blood pressure–lowering therapy.
Key findings:
- Out of 10,000 individuals, 1,807 had their treatment modified based on Lp(a).
- 217–255 quality-adjusted life years gained in Australia and the UK.
- Cost-effectiveness ratios: $12,134 AUD (cost-effective) and −£3,491 GBP (cost-saving).
- From a societal perspective, testing saved $85 AUD and £263 GBP per person.
- Modeling across multiple countries showed Lp(a) testing to be cost-saving everywhere.
Takeaway: Lp(a) testing in primary prevention reclassifies risk, guides therapy, and saves costs—supporting its adoption as a preventive strategy against CVD.
This study makes a compelling case for integrating Lp(a) measurement into routine cardiovascular risk assessment.”
Title: Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis
Author: Jedidiah I. Morton, Florian Kronenberg, Magdalena Daccord, Nicola Bedlington, Marius Geant, Tobias Silberzahn, Zhenyue Chen, Jean-Luc Eisele, Bogi Eliasen, Mariko Harada-Shiba, Marc Rijken, Albert Wiegman, George Thanassoulis, Pia R. Kamstrup, Iñaki Gutierrez-Ibarluzea, Pablo Coral, Raul D. Santos, Erik Stroes, Michal Vrablik, Gerald F. Watts, Christie M. Ballantyne, Samia Mor, Børge G. Nordestgaard, Kausik K. Ray, Stephen J. Nicholls, Zanfina Ademi
Read the full article here.
Stay updated with Hemostasis Today.
-
Dec 17, 2025, 15:24Laura Dormer on a Motor Relearning Program for Chronic Stroke Patients
-
Dec 17, 2025, 15:01WSO: United Nations Has Formally Adopted the Political Declaration on NCDs and Mental Health
-
Dec 17, 2025, 14:44Bryan Unger: 1st Patient Has Been Enrolled in NuvOx Therapeutics’ Phase IIb NOVEL Trial
-
Dec 17, 2025, 14:29Sarah Richardson: Feeling So Proud to Be a Part of the Advocacy Team for the HFA
-
Dec 17, 2025, 06:28Wolfgang Miesbach on Linus Völker’s Presentation of Caplacizumab as Frontline Therapy for iTTP
-
Dec 17, 2025, 06:11Lisa Murphy Thanks Stroke Foundation Team for An Impactful, Rewarding and Incredible Year
-
Dec 17, 2025, 06:05Emmanuel J Favaloro Shares A Study on AI and Machine Learning in Thrombosis and Hemostasis
-
Dec 17, 2025, 05:54Michael Bruckman: Fantastic to See Platelet-Inspired Nanoparticles Gaining Attention!
-
Dec 17, 2025, 04:00Peter Verhamme on Genetic Predisposition to Thromboembolism and COVID